688266 泽璟制药-U
已收盘 08-21 15:00:00
资讯
新帖
简况
每周股票复盘：泽璟制药（688266）重新递表港交所
证券之星 · 08-16
每周股票复盘：泽璟制药（688266）重新递表港交所
泽璟制药（688266）披露重新向香港联交所递交H股发行上市申请并刊发申请资料的公告，8月13日股价上涨0.27%
证券之星 · 08-13
泽璟制药（688266）披露重新向香港联交所递交H股发行上市申请并刊发申请资料的公告，8月13日股价上涨0.27%
新股消息 | 泽璟制药(688266.SH)再度递表港交所
智通财经 · 08-13
新股消息 | 泽璟制药(688266.SH)再度递表港交所
每周股票复盘：泽璟制药（688266）首次半年度盈利6.4亿元
证券之星 · 08-09
每周股票复盘：泽璟制药（688266）首次半年度盈利6.4亿元
泽璟制药（688266）2026年中报简析：营收净利润同比双双增长，盈利能力上升
证券之星 · 08-02
泽璟制药（688266）2026年中报简析：营收净利润同比双双增长，盈利能力上升
泽璟制药(688266)6月30日股东户数1.37万户，较上期增加64.17%
证券之星 · 08-01
泽璟制药(688266)6月30日股东户数1.37万户，较上期增加64.17%
泽璟制药(688266.SH)发布半年度业绩，归母净利润6.4亿元，同比扭亏为盈
智通财经 · 07-31
泽璟制药(688266.SH)发布半年度业绩，归母净利润6.4亿元，同比扭亏为盈
富国基金朱少醒旗下基金二季报出炉！中际旭创(300308.SZ)、泽璟制药(688266.SH)首度进入前十大重仓股
智通财经 · 07-21
富国基金朱少醒旗下基金二季报出炉！中际旭创(300308.SZ)、泽璟制药(688266.SH)首度进入前十大重仓股
泽璟制药（688266）披露股票交易异常波动公告，7月3日股价上涨4.91%
证券之星 · 07-03
泽璟制药（688266）披露股票交易异常波动公告，7月3日股价上涨4.91%
7月3日泽璟制药（688266）龙虎榜数据：机构净买入4.36亿元，北向资金净卖出3926.97万元
证券之星 · 07-03
7月3日泽璟制药（688266）龙虎榜数据：机构净买入4.36亿元，北向资金净卖出3926.97万元
泽璟制药（688266）披露2025年年度股东会决议公告，6月29日股价上涨7.13%
证券之星 · 06-29
泽璟制药（688266）披露2025年年度股东会决议公告，6月29日股价上涨7.13%
每周股票复盘：泽璟制药（688266）2025年年度股东会各项议案均获通过
证券之星 · 06-28
每周股票复盘：泽璟制药（688266）2025年年度股东会各项议案均获通过
新股消息 | 泽璟制药(688266.SH)港股IPO招股书失效
智通财经 · 06-22
新股消息 | 泽璟制药(688266.SH)港股IPO招股书失效
每周股票复盘：泽璟制药（688266）吉卡昔替尼获准治重度斑秃
证券之星 · 06-20
每周股票复盘：泽璟制药（688266）吉卡昔替尼获准治重度斑秃
泽璟制药(688266.SH)：盐酸吉卡昔替尼片治疗重度斑秃适应症上市申请获得批准
智通财经 · 06-15
泽璟制药(688266.SH)：盐酸吉卡昔替尼片治疗重度斑秃适应症上市申请获得批准
每周股票复盘：泽璟制药（688266）ZG005/ZG006临床进展亮相ASCO
证券之星 · 06-07
每周股票复盘：泽璟制药（688266）ZG005/ZG006临床进展亮相ASCO
泽璟制药（688266）披露2025年年度股东会通知，6月1日股价下跌0.31%
证券之星 · 06-01
泽璟制药（688266）披露2025年年度股东会通知，6月1日股价下跌0.31%
股市必读：泽璟制药（688266）5月29日披露最新机构调研信息
证券之星 · 06-01
股市必读：泽璟制药（688266）5月29日披露最新机构调研信息
每周股票复盘：泽璟制药（688266）注射用人促甲状腺素β III期临床达主要终点
证券之星 · 05-10
每周股票复盘：泽璟制药（688266）注射用人促甲状腺素β III期临床达主要终点
泽璟制药（688266）披露注射用人促甲状腺素β III期临床试验达到预设主要终点，5月8日股价下跌2.92%
证券之星 · 05-08
泽璟制药（688266）披露注射用人促甲状腺素β III期临床试验达到预设主要终点，5月8日股价下跌2.92%
加载更多
公司概况
公司名称：
苏州泽璟生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2020-01-23
主营业务：
苏州泽璟生物制药股份有限公司的主营业务是化学新药及生物新药的研发、生产及销售。公司的主要产品是甲苯磺酸多纳非尼片、盐酸吉卡昔替尼片、重组人凝血酶、注射用人促甲状腺素β。
发行价格：
33.76
{"stockData":{"symbol":"688266","market":"SH","secType":"STK","nameCN":"泽璟制药-U","latestPrice":128.71,"timestamp":1787295600000,"preClose":138.34,"halted":0,"volume":8739361,"delay":0,"changeRate":-0.0696,"floatShares":265000000,"shares":265000000,"eps":2.0773,"marketStatus":"已收盘","change":-9.63,"latestTime":"08-21 15:00:00","open":134,"high":135.46,"low":125.54,"amount":1135000000,"amplitude":0.0717,"askPrice":128.71,"askSize":5,"bidPrice":128.7,"bidSize":111,"shortable":0,"etf":0,"ttmEps":2.0773,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":5,"adr":0,"adjPreClose":138.34,"symbolType":"stock_kcb","openAndCloseTimeList":[[1787275800000,1787283000000],[1787288400000,1787295600000]],"highLimit":152.17,"lowLimit":124.51,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":264708186,"isCdr":false,"pbRate":19.8,"roa":"--","peRate":61.960237,"roe":"45.7%","epsLYR":-0.62,"committee":0.186147,"marketValue":34071000000,"turnoverRate":0.033,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-08-24。","afterMarket":{"amount":231678,"volume":1800,"close":128.71,"buyVolume":1200,"sellVolume":0,"time":1787297637746,"indexStatus":"已收盘 08-21 15:30:00","preClose":138.34},"floatMarketCap":34071000000},"requestUrl":"/m/hq/s/688266","defaultTab":"news","newsList":[{"id":"2659751801","title":"每周股票复盘：泽璟制药（688266）重新递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2659751801","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659751801?lang=zh_cn&edition=full","pubTime":"2026-08-16 01:47","pubTimestamp":1786816031,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，泽璟制药报收于120.4元，较上周的121.7元下跌1.07%。本周，泽璟制药8月10日盘中最高价报127.74元。泽璟制药当前最新总市值318.71亿元，在化学制药板块市值排名12/149，在两市A股市值排名642/5207。本周关注点公司公告汇总：泽璟制药重新向香港联交所递交H股发行上市申请并刊发申请资料。本次发行尚需中国证监会、香港证监会及港交所等批准，存在不确定性。公司将及时履行信息披露义务，提醒投资者注意风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266","BK1191","BK1574","01477","HEXmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659016846","title":"泽璟制药（688266）披露重新向香港联交所递交H股发行上市申请并刊发申请资料的公告，8月13日股价上涨0.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659016846","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659016846?lang=zh_cn&edition=full","pubTime":"2026-08-13 22:18","pubTimestamp":1786630701,"startTime":"0","endTime":"0","summary":"截至2026年8月13日收盘，泽璟制药报收于120.22元，较前一交易日上涨0.27%，最新总市值为318.23亿元。近日，苏州泽璟生物制药股份有限公司披露《关于重新向香港联交所递交H股发行上市申请并刊发申请资料的公告》。公告显示，公司于2026年8月12日重新向香港联合交易所有限公司递交发行H股股票并在香港联交所主板上市的申请，并在港交所网站刊登了申请材料。本次发行尚需中国证监会、香港证监会及港交所等批准，存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300039649.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1191","688266","01477","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659863741","title":"新股消息 | 泽璟制药(688266.SH)再度递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2659863741","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659863741?lang=zh_cn&edition=full","pubTime":"2026-08-13 06:24","pubTimestamp":1786573458,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所8月12日披露，苏州泽璟生物制药股份有限公司向港交所主板递交上市申请，中金公司为独家保荐人。该公司曾于2025年12月19日递表港交所。招股书显示，泽璟制药是一家综合生物制药企业，专注于创新型小分子及生物制剂疗法的发现、研发及商业化，策略聚焦于肿瘤学、自身免疫性疾病、止血╱血液病领域。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK1574","BK1191","688266","HEXmain","IPOS","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658673625","title":"每周股票复盘：泽璟制药（688266）首次半年度盈利6.4亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658673625","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658673625?lang=zh_cn&edition=full","pubTime":"2026-08-09 01:21","pubTimestamp":1786209669,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，泽璟制药报收于121.7元，较上周的122.1元下跌0.33%。本周，泽璟制药8月7日盘中最高价报122.0元。本周关注点来自业绩披露要点：公司自成立以来首次实现半年度盈利，归母净利润为64,001.11万元。机构调研要点2026年上半年，公司实现营业收入120,537.96万元，同比增长220.88%，主要因确认技术授权收入66,230.95万元及商业化产品销售增长；归母净利润达64,001.11万元，首次实现半年度盈利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01477","BK0239","BK1191","688266","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656311586","title":"泽璟制药（688266）2026年中报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2656311586","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656311586?lang=zh_cn&edition=full","pubTime":"2026-08-02 06:01","pubTimestamp":1785621676,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期泽璟制药发布2026年中报。截至本报告期末，公司营业总收入12.05亿元，同比上升220.88%，归母净利润6.4亿元，同比上升979.09%。本报告期泽璟制药盈利能力上升，毛利率同比增幅5.55%，净利率同比增幅363.94%。持有泽璟制药最多的基金为汇添富创新医药混合A，目前规模为89.62亿元，最新净值1.6913，较上一交易日上涨0.21%，近一年下跌15.46%。本文数据来源于泽璟制药2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200001246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01477","688266"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656182573","title":"泽璟制药(688266)6月30日股东户数1.37万户，较上期增加64.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656182573","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656182573?lang=zh_cn&edition=full","pubTime":"2026-08-01 17:02","pubTimestamp":1785574924,"startTime":"0","endTime":"0","summary":"证券之星消息，近日泽璟制药披露，截至2026年6月30日公司股东户数为1.37万户，较3月31日增加5354.0户，增幅为64.17%。在化学制药行业个股中，泽璟制药股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.6万户。从股价来看，2026年3月31日至2026年6月30日，泽璟制药区间涨幅为18.08%，在此期间股东户数增加5354.0户，增幅为64.17%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080100012774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1191","688266","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655039357","title":"泽璟制药(688266.SH)发布半年度业绩，归母净利润6.4亿元，同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2655039357","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655039357?lang=zh_cn&edition=full","pubTime":"2026-07-31 18:28","pubTimestamp":1785493730,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泽璟制药(688266.SH)披露2026年半年度报告，报告期公司实现营收12.05亿元，同比增长220.88%;归属于上市公司股东的净利润6.4亿元，同比扭亏为盈;扣非净利润6.17亿元，同比扭亏为盈;基本每股收益2.42元。营业收入大幅增长主要系公司报告期确认产品技术授权许可相关收入6.62亿元，同时商业化产品的销售收入与上年同期相比增长44.30%。归属于上市公司股东的净资产较上年同期增加59.24%，公司自成立以来首次实现半年度盈利，带动净资产相应增长。同时，扣除非经常性损益前后的每股收益、加权平均净资产收益率均由负转正。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688266","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653322764","title":"富国基金朱少醒旗下基金二季报出炉！中际旭创(300308.SZ)、泽璟制药(688266.SH)首度进入前十大重仓股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653322764","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653322764?lang=zh_cn&edition=full","pubTime":"2026-07-21 16:08","pubTimestamp":1784621322,"startTime":"0","endTime":"0","summary":"截至二季度末，中际旭创、泽璟制药首度进入该基金的前十大重仓股，分别成为第六大、第七大重仓股。同时，中国平安、滨江集团再度进入该基金的前十大重仓股，徐工机械、紫金矿业、瑞丰新材、贵州茅台集体退出该基金的前十大重仓股。截至二季度末，该基金继续重仓持有宁波银行，并且持股数量与上个季度保持不变。截至2026年二季度末，该基金已连续24个季度重仓宁波银行，持仓市值达14.85亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470316.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1303224171.USD","688266","BK1191","IE0034224299.USD","LU1064130708.USD","300308","BK0070","LU0164939612.USD","LU0572944931.SGD","01477","LU2399975544.HKD","LU0327786744.USD","LU1720050803.USD","LU0039217434.USD","IE0032431581.USD","SGXZ49509284.SGD","LU1770034418.SGD","LU0708995583.HKD","LU2008162690.USD","LU1655091616.SGD","LU0320764599.SGD","LU1251922891.USD","HK0000320223.HKD","LU1961090484.USD","LU0469268626.HKD","LU1580142542.USD","LU0348735423.USD","LU1794554557.SGD","LU2495084118.USD","LU1064131003.USD","SG9999011746.SGD","LU1979443071.USD","LU0348827113.USD","LU0210526637.USD","LU2778985437.USD","LU1781817850.SGD","LU1997245177.USD","SGXZ81163826.USD","LU1820825898.SGD","LU2148510915.USD","LU0231483743.USD","91530","LU0634319403.HKD","BK0167","LU0871576103.HKD","LU2476274308.USD","LU2476274720.SGD","LU1719994722.HKD","LU2177674079.SGD","LU0082770016.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648661537","title":"泽璟制药（688266）披露股票交易异常波动公告，7月3日股价上涨4.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648661537","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648661537?lang=zh_cn&edition=full","pubTime":"2026-07-03 22:04","pubTimestamp":1783087465,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，泽璟制药报收于143.0元，较前一交易日上涨4.91%，最新总市值为378.53亿元。该股当日开盘135.0元，最高146.02元，最低125.69元，成交额达19.35亿元，换手率为5.45%。近日，泽璟制药发布《股票交易异常波动公告》。公告显示，公司股票交易连续3个交易日内日收盘价格涨幅偏离值累计达到30%，构成股票交易异常波动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300045210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1191","688266","01477","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648969650","title":"7月3日泽璟制药（688266）龙虎榜数据：机构净买入4.36亿元，北向资金净卖出3926.97万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2648969650","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648969650?lang=zh_cn&edition=full","pubTime":"2026-07-03 17:44","pubTimestamp":1783071878,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年7月3日公布的交易公开信息显示，泽璟制药因有价格涨跌幅限制的连续3个交易日内收盘价格涨幅偏离值累计达到30%的证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年7月3日收盘，泽璟制药报收于143.0元，上涨4.91%，换手率5.45%，成交量14.43万手，成交额19.35亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入4.36亿元，北向资金合计净卖出3926.97万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300032992.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239","BK1574","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647378221","title":"泽璟制药（688266）披露2025年年度股东会决议公告，6月29日股价上涨7.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647378221","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647378221?lang=zh_cn&edition=full","pubTime":"2026-06-29 18:06","pubTimestamp":1782727603,"startTime":"0","endTime":"0","summary":"截至2026年6月29日收盘，泽璟制药报收于114.41元，较前一交易日上涨7.13%，最新总市值为302.85亿元。公司于近日披露《泽璟制药2025年年度股东会决议公告》。出席会议的股东及代理人共554人，代表有表决权股份总数的52.1932%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900029041.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1191","688266","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646315498","title":"每周股票复盘：泽璟制药（688266）2025年年度股东会各项议案均获通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2646315498","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646315498?lang=zh_cn&edition=full","pubTime":"2026-06-28 03:39","pubTimestamp":1782589151,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，泽璟制药报收于106.8元，较上周的89.69元上涨19.08%。本周，泽璟制药6月26日盘中最高价报109.36元。本周关注点公司公告汇总：泽璟制药2025年年度股东会各项议案均获通过，出席股东及代理人共554人，代表有表决权股份总数的52.1932%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800001136.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","01477","BK1191","BK1574","688266"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645744010","title":"新股消息 | 泽璟制药(688266.SH)港股IPO招股书失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2645744010","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645744010?lang=zh_cn&edition=full","pubTime":"2026-06-22 10:53","pubTimestamp":1782096824,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，苏州泽璟生物制药股份有限公司(简称：泽璟制药，688266.SH)于2025年12月19日所递交的港股招股书满6个月，于2026年6月19日失效，递表时中金公司为其独家保荐人。招股书显示，泽璟制药为一家综合生物制药企业，专注于创新型小分子及生物制剂疗法的发现、研发及商业化，策略聚焦于肿瘤学、自身免疫性疾病、止血/血液病领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456752.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","IPOS","BK4588","BK1191","688266","01477","BK4585","VXUS","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644063790","title":"每周股票复盘：泽璟制药（688266）吉卡昔替尼获准治重度斑秃","url":"https://stock-news.laohu8.com/highlight/detail?id=2644063790","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644063790?lang=zh_cn&edition=full","pubTime":"2026-06-20 02:28","pubTimestamp":1781893693,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，泽璟制药报收于89.69元，较上周的92.88元下跌3.43%。本周关注点公司公告汇总：盐酸吉卡昔替尼片治疗成人重度斑秃适应症获批上市。公司公告汇总泽璟制药关于自愿披露盐酸吉卡昔替尼片治疗重度斑秃适应症上市申请获得批准的公告苏州泽璟生物制药股份有限公司收到国家药品监督管理局核准签发的《药品注册证书》，公司自主研发的盐酸吉卡昔替尼片用于治疗成人重度斑秃的上市申请获得批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000000717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1574","BK1191","688266","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643272432","title":"泽璟制药(688266.SH)：盐酸吉卡昔替尼片治疗重度斑秃适应症上市申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2643272432","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643272432?lang=zh_cn&edition=full","pubTime":"2026-06-15 18:16","pubTimestamp":1781518615,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泽璟制药 发布公告，近日，公司收到国家药品监督管理局核准签发的《药品注册证书》，公司自主研发的盐酸吉卡昔替尼片用于治疗成人重度斑秃的上市申请获得批准。这是继用于治疗中、高危骨髓纤维化的适应症获批后，盐酸吉卡昔替尼片第二个获批上市的适应症，也是盐酸吉卡昔替尼片首个获批的治疗免疫炎症性疾病的临床适应症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","688266","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641122074","title":"每周股票复盘：泽璟制药（688266）ZG005/ZG006临床进展亮相ASCO","url":"https://stock-news.laohu8.com/highlight/detail?id=2641122074","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2641122074?lang=zh_cn&edition=full","pubTime":"2026-06-07 02:00","pubTimestamp":1780768845,"startTime":"0","endTime":"0","summary":"截至2026年6月5日收盘，泽璟制药报收于90.67元，较上周的99.93元下跌9.27%。本周，泽璟制药6月1日盘中最高价报105.59元。公司公告汇总：泽璟制药将于2026年6月26日召开2025年年度股东会，采用现场与网络投票结合方式。泽璟制药关于自愿披露ZG005和ZG006在2026年美国临床肿瘤学会年会发布临床数据及最新进展的公告苏州泽璟生物制药股份有限公司自主研发的新药ZG005和ZG006的临床研究数据及最新进展在2026年美国临床肿瘤学会年会上发布。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060700000522.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640898950","title":"泽璟制药（688266）披露2025年年度股东会通知，6月1日股价下跌0.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640898950","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640898950?lang=zh_cn&edition=full","pubTime":"2026-06-01 22:15","pubTimestamp":1780323318,"startTime":"0","endTime":"0","summary":"截至2026年6月1日收盘，泽璟制药报收于99.62元，较前一交易日下跌0.31%，最新总市值为263.7亿元。近日，泽璟制药发布《关于召开2025年年度股东会的通知》。公告显示，苏州泽璟生物制药股份有限公司将于2026年6月26日召开2025年年度股东会，会议采取现场投票与网络投票相结合的方式，股权登记日为2026年6月22日。会议审议包括2025年年度报告、董事会工作报告、利润分配预案、续聘2026年度审计机构、董事薪酬标准及薪酬管理制度等议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100040858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640851849","title":"股市必读：泽璟制药（688266）5月29日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2640851849","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640851849?lang=zh_cn&edition=full","pubTime":"2026-06-01 03:42","pubTimestamp":1780256530,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，泽璟制药报收于99.93元，上涨3.23%，换手率1.72%，成交量4.54万手，成交额4.41亿元。当日关注点来自交易信息汇总：5月29日主力资金净流入448.35万元，占总成交额1.02%。来自机构调研要点：泽璟制药将在2026年ASCO年会公布ZG005联合贝伐珠单抗用于晚期肝细胞癌一线治疗的Ⅱ期临床研究数据，该研究入选大会口头报告。注射用ZG006联合瀚森制药HS-20093治疗广泛期小细胞肺癌的临床试验已获国家药监局批准，公司正推进合作事项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100001562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634741496","title":"每周股票复盘：泽璟制药（688266）注射用人促甲状腺素β III期临床达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2634741496","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2634741496?lang=zh_cn&edition=full","pubTime":"2026-05-10 02:29","pubTimestamp":1778351350,"startTime":"0","endTime":"0","summary":"本周关注点公司公告汇总：注射用人促甲状腺素β III期临床试验达到预设主要终点。公司公告汇总泽璟制药关于自愿披露注射用人促甲状腺素β III期临床试验达到预设主要终点的公告苏州泽璟生物制药股份有限公司自主研发的注射用人促甲状腺素βIII期临床试验达到预设主要终点，该试验用于评价其在分化型甲状腺癌患者术后放射性碘清甲治疗的有效性和安全性。注射用人促甲状腺素β已于2026年1月获批用于甲状腺癌术后随访中的协同诊断。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000000888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633300431","title":"泽璟制药（688266）披露注射用人促甲状腺素β III期临床试验达到预设主要终点，5月8日股价下跌2.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633300431","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2633300431?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:35","pubTimestamp":1778232935,"startTime":"0","endTime":"0","summary":"公司于近日披露《关于自愿披露注射用人促甲状腺素β III期临床试验达到预设主要终点的公告》。公告显示，苏州泽璟生物制药股份有限公司自主研发的注射用人促甲状腺素βIII期临床试验达到预设主要终点，该试验用于评价其在分化型甲状腺癌患者术后放射性碘清甲治疗的有效性和安全性。注射用人促甲状腺素β已于2026年1月获批用于甲状腺癌术后随访中的协同诊断。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800031507.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787339148516,"stockEarnings":[{"period":"1week","weight":0.069},{"period":"1month","weight":-0.0806},{"period":"3month","weight":0.261},{"period":"6month","weight":0.3632},{"period":"1year","weight":0.1919},{"period":"ytd","weight":0.3885}],"compareEarnings":[{"period":"1week","weight":-0.0056},{"period":"1month","weight":0.0099},{"period":"3month","weight":-0.0505},{"period":"6month","weight":-0.0433},{"period":"1year","weight":0.0356},{"period":"ytd","weight":-0.016}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"苏州泽璟生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"13698人(较上一季度增加64.17%)","perCapita":"19324股","listingDate":"2020-01-23","address":"江苏省苏州市昆山市玉山镇晨丰路209号","registeredCapital":"26470万元","survey":" 苏州泽璟生物制药股份有限公司的主营业务是化学新药及生物新药的研发、生产及销售。公司的主要产品是甲苯磺酸多纳非尼片、盐酸吉卡昔替尼片、重组人凝血酶、注射用人促甲状腺素β。","listedPrice":33.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泽璟制药-U(688266)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泽璟制药-U(688266)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泽璟制药-U,688266,泽璟制药-U股票,泽璟制药-U股票老虎,泽璟制药-U股票老虎国际,泽璟制药-U行情,泽璟制药-U股票行情,泽璟制药-U股价,泽璟制药-U股市,泽璟制药-U股票价格,泽璟制药-U股票交易,泽璟制药-U股票购买,泽璟制药-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泽璟制药-U(688266)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泽璟制药-U(688266)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}